Issue Date: September 14, 2009
Targeted Genetics Has Deal With Genzyme
Targeted Genetics has sold manufacturing and other technology related to adeno-associated viral vectors to Genzyme for up to $7 million. Genzyme licensed the technology back to the Seattle-based firm for use in specified drug discovery programs. Since November 2008, Targeted Genetics has reduced its workforce by 80% to 15 employees. CEO B. G. Susan Robinson says the company now has enough cash to continue operating through 2010.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society